Fanny Rocher
Research Subjects
Fanny Rocher has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Olivier Gérard
Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France
3 shared publications - Milou-Daniel Drici
Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France
3 shared publications - Diane Merino
Department of Psychiatry, University Hospital of Nice, 06000 Nice, France
2 shared publications - Laurent Chouchana
Pharmacovigilance Regional Centre, Pharmacology Department, Cochin Hospital, APHP UMR1343 INSERM Université Paris Cité Paris France
2 shared publications - Nouha Ben Othman
Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France
2 shared publications Adrien Sanchez
Dermatologie
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- 7 September 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessMental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase
Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3
- 4 May 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently investigated ADRs and genetic polymorphisms in this population. Finally, we investigated the specific effect of CYP1A2 variants in the occurrence of ADRs and/or lack of therapeutic effect. Condition being studied: This review focuses on children, adolescents and youth treated with antipsychotics (olanzapine, clozapine, loxapine) and experienced adverse drug reactions.
- 4 May 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Protocol: Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review
Review question / Objective: In children and youth treated with olanzapine, clozapine, or loxapine and having undergone genotyping, which are the pharmacogenetic variants underlying the antipsychotics' adverse drug reactions and efficacy? What are the most frequently investigated adverse drug reactions and variants ? What is described about the specific effect of CYP1A2 variants ? Therefore, we aimed to review the pharmacogenetic variants underlying olanzapine, clozapine and loxapine ADRs and/or efficacy, in children and youth having undergone genotyping. Then, assessed the most frequently investigated ADRs and genetic polymorphisms in this population. Finally, we investigated the specific effect of CYP1A2 variants in the occurrence of ADRs and/or lack of therapeutic effect. Condition being studied: This review focuses on children, adolescents and youth treated with antipsychotics (olanzapine, clozapine, loxapine) and experienced adverse drug reactions.
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A185-A186
Myopathie nécrosante chez un patient atteint d’un mélanome avancé traité par immunothérapie après une vaccination contre la COVID-19
- 19 November 2021
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie - FMC
- Vol. 1 (8) , A185-A186
Myopathie nécrosante chez un patient atteint d’un mélanome avancé traité par immunothérapie après une vaccination contre la COVID-19
- 21 June 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (11) , 3357-3364
Immune checkpoint inhibitors-induced nephropathy: a French national survey
Immune checkpoint inhibitors (ICIs), aiming to foster cancer-targeted immune response, proved to be effective in several advanced malignancies at the price of immune-related adverse events affecting various organs, notably the kidneys. Herein, a retrospective descriptive analysis was performed on all biopsy-confirmed cases of ICI-induced nephropathy notified to the French Pharmacovigilance database to date. Data were gathered about patients’ characteristics, acute kidney injuries and histopathological features. A total of 63 biopsy-proven cases were included for analysis. Immune-related nephropathy occurred after a mean of 105.5 ± 98.6 (standard deviation) days after the introduction of the ICI. Kidney Disease: Improving Global Outcomes acute kidney injury stage 3 occurred in 36.5% of patients, and the mean peak serum creatinine was 288 µmol/L. Histopathology suggested acute tubule-interstitial nephritis in 52 patients (83%), while signs of acute tubular necrosis were found in 18 (29%) and glomerular involvement in 5 of them (8%). Another immune-related adverse event was documented in 25 patients (39.7%). Patients were treated with corticosteroids in 88.9% of cases. All in all, 27.0% fully recovered, 54.0% partially recovered, 12.7% did not recover. Rechallenge was attempted in 19 patients and one patient relapsed. Three-quarters of patients received a medication known to cause acute tubule-interstitial nephritis. The major limits of this study are those inherent to pharmacovigilance studies, such as its retrospective nature and incomplete data. Although it cannot pretend drawing any pathophysiological conclusion, this study depicts the clinical and histopathological pictures of ICI-induced nephropathies in a large cohort of biopsied patients with all grades of severity.
- 21 June 2021
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (11) , 3357-3364
Immune checkpoint inhibitors-induced nephropathy: a French national survey
Immune checkpoint inhibitors (ICIs), aiming to foster cancer-targeted immune response, proved to be effective in several advanced malignancies at the price of immune-related adverse events affecting various organs, notably the kidneys. Herein, a retrospective descriptive analysis was performed on all biopsy-confirmed cases of ICI-induced nephropathy notified to the French Pharmacovigilance database to date. Data were gathered about patients’ characteristics, acute kidney injuries and histopathological features. A total of 63 biopsy-proven cases were included for analysis. Immune-related nephropathy occurred after a mean of 105.5 ± 98.6 (standard deviation) days after the introduction of the ICI. Kidney Disease: Improving Global Outcomes acute kidney injury stage 3 occurred in 36.5% of patients, and the mean peak serum creatinine was 288 µmol/L. Histopathology suggested acute tubule-interstitial nephritis in 52 patients (83%), while signs of acute tubular necrosis were found in 18 (29%) and glomerular involvement in 5 of them (8%). Another immune-related adverse event was documented in 25 patients (39.7%). Patients were treated with corticosteroids in 88.9% of cases. All in all, 27.0% fully recovered, 54.0% partially recovered, 12.7% did not recover. Rechallenge was attempted in 19 patients and one patient relapsed. Three-quarters of patients received a medication known to cause acute tubule-interstitial nephritis. The major limits of this study are those inherent to pharmacovigilance studies, such as its retrospective nature and incomplete data. Although it cannot pretend drawing any pathophysiological conclusion, this study depicts the clinical and histopathological pictures of ICI-induced nephropathies in a large cohort of biopsied patients with all grades of severity.
- Open Access
- 28 April 2021
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 19 (2) , 2360
Patterns of medication errors involving pediatric population reported to the French Medication Error Guichet
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology
- 28 April 2021
- Published by JCFCorp SG PTE LTD in Pharmacy Practice
- Vol. 19 (2) , 2360
Open AccessPatterns of medication errors involving pediatric population reported to the French Medication Error Guichet
Pharmacy Practice is a free full-text journal with a scope on the practice of pharmacy. Pharmacy Practice covers pharmaceutical care, social pharmacy, pharmacy education, process and outcome research, health promotion and education, health informatics, pharmacoepidemiology
- 26 November 2020
- Published by Elsevier in Archives de Pédiatrie
- Vol. 28 (1) , 101-103
Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia
- 26 November 2020
- Published by Elsevier in Archives de Pédiatrie
- Vol. 28 (1) , 101-103
Tolerance induction to deferasirox in a child with transfusion-dependent beta thalassemia
- 27 April 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (17) , 1394-1395
GIANT URTICARIA AND PERSISTENT NEUTRALIZING ANTIBODIES AFTER THE FIRST NATALIZUMAB INFUSION
- 27 April 2010
- Published by Wolters Kluwer Health in Neurology
- Vol. 74 (17) , 1394-1395
GIANT URTICARIA AND PERSISTENT NEUTRALIZING ANTIBODIES AFTER THE FIRST NATALIZUMAB INFUSION